Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO and Pembrolizumab in STK11 Pathway-Deficient NSCLC
NCT06219174Phase 2Suspended
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2024
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eflornithine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 12 months and Objective Response Rate at 5 years. Started Aug 2024; status: suspended.
02
Drugs
eflornithine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06219174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219174.